10-Q: Yubo International Biotech Reports Q2 2026 Results, No Revenue

Yubo International Biotech Limited filed its Q2 2026 Form 10-Q, reporting zero revenue for the period and continued net losses, raising substantial doubt about its going concern status.

Summary

• Yubo International Biotech Limited filed its quarterly report for the period ended June 30, 2026.
• The company reported zero revenue for both the three and six-month periods ended June 30, 2026, and 2025.
• Operating expenses decreased in both the three-month and six-month periods compared to the prior year.
• Net loss for the three months ended June 30, 2026, was $268,721, an increase from $249,722 in the prior year.
• Net loss for the six months ended June 30, 2026, was $563,747, a decrease from $592,136 in the prior year.
• The company had cash and cash equivalents of $11,989 as of June 30, 2026, and negative working capital of $2,744,500.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• A financial support letter from major shareholder Jun Wang provides assurance for 12 months from March 31, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's continued lack of revenue, significant net losses, and substantial doubt about its ability to continue as a going concern, despite a shareholder support letter.

Positives

• Operating expenses decreased by 4.3% for the three months ended June 30, 2026, compared to the same period in 2025.
• Operating expenses decreased by 10.8% for the six months ended June 30, 2026, compared to the same period in 2025.
• A financial support letter from the largest shareholder, Jun Wang, provides assurance for meeting liabilities for 12 months from March 31, 2026.

Negatives

• The company reported zero sales and zero cost of goods sold for both the three and six-month periods ended June 30, 2026 and 2025.
• Net loss for the three months ended June 30, 2026, increased by 7.6% to $268,721 from $249,722 in the prior year.
• The company had cash and cash equivalents of only $11,989 as of June 30, 2026.
• The company reported negative working capital of $2,744,500 as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has not yet established an ongoing source of revenues and cash flows sufficient to cover its operating costs.

Risks

• The VIE structure carries unique risks, including potential non-compliance with PRC laws and regulations, which could lead to severe penalties or loss of control over the VIE.
• The company's ability to continue as a going concern is dependent on obtaining additional capital resources and successful future operations.
• Future financing may cause significant dilution to existing stockholders and could include restrictive covenants.
• The PRC government has significant authority to intervene in China operations, and new regulations could adversely affect business.
• Enforcing civil liabilities in China against directors and officers residing there may be difficult.
• The Holding Foreign Companies Accountable Act (HFCA Act) could lead to delisting if the company's auditor is not subject to PCAOB inspections.
• Cybersecurity review measures in China could lead to operational disruptions or penalties.
• Changes in PRC laws and regulations regarding data security, privacy, and cross-border data transfer could impact operations and increase costs.

Future Outlook

The company has not generated revenue and continues to incur losses. Its ability to continue as a going concern is dependent on obtaining additional capital resources and generating profitable operations in the future. Management plans to obtain capital from management and significant shareholders and seek third-party equity and/or debt financing. A financial support letter from a major shareholder provides assurance for 12 months from March 31, 2026.

Management Comments

• Management is actively exploring more effective sales approaches and distribution channels.
• Management believes that with the financial support letter, the company's cash on hand will be sufficient to meet anticipated cash requirements through 2026.
• Management intends to continue working toward identifying and obtaining new sources of financing and may raise additional capital in 2026.
• Management does not expect disclosure controls or internal control over financial reporting to prevent or detect all errors and fraud, acknowledging inherent limitations.

Industry Context

StockSavvy.ai notes that Yubo International Biotech operates in the biotechnology sector, which is often characterized by long development cycles, significant R&D investment, and regulatory hurdles. The company's reliance on a VIE structure for its China operations is common in industries with foreign investment restrictions in China, but it introduces specific legal and operational risks.

Comparison to Industry Standards

• The biotechnology industry typically requires substantial capital investment for research and development, and many companies experience losses in early stages.
• Companies operating in China, especially those utilizing VIE structures, face increasing regulatory scrutiny regarding data security, cybersecurity, and foreign investment.
• The lack of revenue generation and continued net losses, coupled with negative working capital, places Yubo International Biotech in a precarious financial position compared to established, revenue-generating biotech firms.

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.

Related Party Transactions

• Due from related parties includes $297,273 to Beijing Zhenhuikang Biotechnology Co., LTD, controlled by a director and significant stockholder of Yubo Beijing.
• Due to related parties includes $1,364,268 to Mr. Jun Wang (President and Director), $129,956 to Mr. Yang Wang (CEO and Director), and $55,486 to Ms. Huang Li (shareholder of Focus One Technology Group Limited).
• On July 23, 2025, Yubo New York entered into a Securities Purchase Agreement with FlyDragon International Limited and ChinaOne Technology Limited, entities controlled by Jun Wang and Yang Wang respectively, for the sale of Class A Common Stock. The consideration was the cancellation of shareholder loans.

Stakeholder Impact

• Shareholders face significant risk due to the company's lack of revenue, continued losses, and going concern issues, which could lead to a substantial decline or worthlessness of their investment.
• Employees may be impacted by potential delays, scaling back, or elimination of operations if adequate funding is not secured.
• Creditors and suppliers may face uncertainty regarding timely payment due to the company's liquidity challenges.

Next Steps

• Continue market research and evaluation, including assessment of market outlook, risk factors, and compliance considerations.
• Actively explore more effective sales approaches and distribution channels.
• Identify and obtain new sources of financing.
• Continue to comply with evolving PRC laws and regulations related to data security, cybersecurity, and foreign investment.

Key Dates

Recommendation

The company exhibits a critical lack of revenue, persistent net losses, and significant going concern doubts, despite a shareholder support letter. The ongoing risks associated with the VIE structure and PRC regulations further compound the negative outlook, making it a highly speculative investment with a strong potential for further value erosion.

Keywords

VIE structure, going concern, biotech, China operations, financial statements, net loss, revenue, shareholder support